insights_auto
Why is DMN up 9.10%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
€0.078
arrow_upward
+9.10%(+0.0065) 1D
Oct 19, 8:05:58 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€0.08
High
€0.08
Low
€0.08
Mkt. cap
154.51M
Avg. vol.
17.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
Open
€0.08
High
€0.08
Low
€0.08
Mkt. cap
154.51M
Avg. vol.
17.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
News stories
From web sources and news partners
HDFC Sky
·
33 minutes ago
Nasdaq Jumps 259 Points to 26,399 as Intel Surges 5.5% and AI Stocks Rebound After Brutal Selloff
TipRanks
·
26 minutes ago
Dow Jones Steady as AI Stocks Rebound from Selloff
TradingView
·
1 hour ago
The Dow Jones Index Opens 0.08% Lower
GuruFocus
·
59 minutes ago
Bank of America Securities Upgrades Dow Inc. (DOW) to Neutral on Rising Chemical Prices
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB